Cargando…
An Overview of siRNA Delivery Strategies for Urological Cancers
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) see...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030829/ https://www.ncbi.nlm.nih.gov/pubmed/35456552 http://dx.doi.org/10.3390/pharmaceutics14040718 |
_version_ | 1784692238636285952 |
---|---|
author | Halib, Nadia Pavan, Nicola Trombetta, Carlo Dapas, Barbara Farra, Rossella Scaggiante, Bruna Grassi, Mario Grassi, Gabriele |
author_facet | Halib, Nadia Pavan, Nicola Trombetta, Carlo Dapas, Barbara Farra, Rossella Scaggiante, Bruna Grassi, Mario Grassi, Gabriele |
author_sort | Halib, Nadia |
collection | PubMed |
description | The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers. |
format | Online Article Text |
id | pubmed-9030829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90308292022-04-23 An Overview of siRNA Delivery Strategies for Urological Cancers Halib, Nadia Pavan, Nicola Trombetta, Carlo Dapas, Barbara Farra, Rossella Scaggiante, Bruna Grassi, Mario Grassi, Gabriele Pharmaceutics Review The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers. MDPI 2022-03-27 /pmc/articles/PMC9030829/ /pubmed/35456552 http://dx.doi.org/10.3390/pharmaceutics14040718 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Halib, Nadia Pavan, Nicola Trombetta, Carlo Dapas, Barbara Farra, Rossella Scaggiante, Bruna Grassi, Mario Grassi, Gabriele An Overview of siRNA Delivery Strategies for Urological Cancers |
title | An Overview of siRNA Delivery Strategies for Urological Cancers |
title_full | An Overview of siRNA Delivery Strategies for Urological Cancers |
title_fullStr | An Overview of siRNA Delivery Strategies for Urological Cancers |
title_full_unstemmed | An Overview of siRNA Delivery Strategies for Urological Cancers |
title_short | An Overview of siRNA Delivery Strategies for Urological Cancers |
title_sort | overview of sirna delivery strategies for urological cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030829/ https://www.ncbi.nlm.nih.gov/pubmed/35456552 http://dx.doi.org/10.3390/pharmaceutics14040718 |
work_keys_str_mv | AT halibnadia anoverviewofsirnadeliverystrategiesforurologicalcancers AT pavannicola anoverviewofsirnadeliverystrategiesforurologicalcancers AT trombettacarlo anoverviewofsirnadeliverystrategiesforurologicalcancers AT dapasbarbara anoverviewofsirnadeliverystrategiesforurologicalcancers AT farrarossella anoverviewofsirnadeliverystrategiesforurologicalcancers AT scaggiantebruna anoverviewofsirnadeliverystrategiesforurologicalcancers AT grassimario anoverviewofsirnadeliverystrategiesforurologicalcancers AT grassigabriele anoverviewofsirnadeliverystrategiesforurologicalcancers AT halibnadia overviewofsirnadeliverystrategiesforurologicalcancers AT pavannicola overviewofsirnadeliverystrategiesforurologicalcancers AT trombettacarlo overviewofsirnadeliverystrategiesforurologicalcancers AT dapasbarbara overviewofsirnadeliverystrategiesforurologicalcancers AT farrarossella overviewofsirnadeliverystrategiesforurologicalcancers AT scaggiantebruna overviewofsirnadeliverystrategiesforurologicalcancers AT grassimario overviewofsirnadeliverystrategiesforurologicalcancers AT grassigabriele overviewofsirnadeliverystrategiesforurologicalcancers |